Company / SG&A Expense
Summit Therapeutics Inc. SG&A Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$556.8M
FY2025
5-year range
$23.6M / $556.8M
FY2021-FY2025
Trend
+824.6%
vs FY2024
Sector context
#32 of 213
Health Care
What the data says
SG&A Expense changed +825% YoY in FY2025, a notable deviation from the 7-year average annual change of +145%.
Based on SEC 10-K filings.
$557M in FY2025 with a 5-year CAGR of +96.0%. Top quartile in the Health Care sector.
Increased from $29M to $557M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +186.8%
- 5-Year CAGR
- +96.0%
- 10-Year CAGR
- -
Sector benchmark
Bottom 15% in Health CareTop 85% of 213This company $556.8M Sector average $722.3M
▼
-22.9% below sector average
Key checks
Key Insights
- Summit Therapeutics Inc.'s sg&a expense has grown for 3 consecutive years.
- 5-year CAGR of +96.0%, indicating consistent growth.
- In FY2025, sg&a expense increased 824.6% year-over-year.
- Ranks #32 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $556.8M | +824.6% |
| FY2024 | $60.2M | +105.8% |
| FY2023 | $29.3M | +23.9% |
| FY2022 | $23.6M | +0.0% |
| FY2021 | $23.6M | +22.8% |
| FY2020 | $19.2M | +70.5% |
| FY2019 | $11.3M | -33.7% |
| FY2018 | $17.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026